LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

Search

Alkermes PLC

Closed

SectorHealthcare

34.42 1.38

Overview

Share price change

24h

Current

Min

33.98

Max

34.6

Key metrics

By Trading Economics

Income

54M

147M

Sales

52M

430M

P/E

Sector Avg

15.623

71.874

EPS

1.05

Profit margin

34.072

Employees

1,800

EBITDA

58M

181M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+13.86% upside

Dividends

By Dow Jones

Next Earnings

30 Apr 2025

Market Stats

By TradingEconomics

Market Cap

487M

5.6B

Previous open

33.04

Previous close

34.42

News Sentiment

By Acuity

50%

50%

174 / 387 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Alkermes PLC Chart

Past performance is not a reliable indicator of future results.

Related News

21 Mar 2025, 21:58 UTC

Acquisitions, Mergers, Takeovers

Global Business Travel Group Cuts Price of Deal for Rival CWT

21 Mar 2025, 16:31 UTC

Major Market Movers

Boeing Shares Rise After Winning $20 Billion Air Force Contract

21 Mar 2025, 23:02 UTC

Acquisitions, Mergers, Takeovers

Ranking the S&P 500s Most Defensive Stocks -- Barrons.com

21 Mar 2025, 22:15 UTC

Acquisitions, Mergers, Takeovers

Riot Platforms: Unit Will Provide $185M to Rhodium on Deal Close >RIOT

21 Mar 2025, 22:13 UTC

Acquisitions, Mergers, Takeovers

Riot Platforms: Motion Filed to Approve Settlement in Rhodium's Bankruptcy Case

21 Mar 2025, 22:12 UTC

Acquisitions, Mergers, Takeovers

Riot Platforms Enters Non-Binding Term Sheet to Buy Certain Assets of Rhodium Encore >RIOT

21 Mar 2025, 22:03 UTC

Top News

Trump to Announce Multibillion-Dollar Jet Fighter -- 4th Update

21 Mar 2025, 21:05 UTC

Top News

The Score: Nvidia, Tesla, Nike and More Stocks That Defined the Week -- WSJ

21 Mar 2025, 20:50 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

21 Mar 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

21 Mar 2025, 20:24 UTC

Top News

Major Indexes Stage Late Rally -- WSJ

21 Mar 2025, 20:01 UTC

Top News

Columbia Yields to Trump in Battle Over Federal Funding -- WSJ

21 Mar 2025, 19:40 UTC

Market Talk

Walmart's Beauty Marketplace Push Puts Ulta Beauty at Risk -- Market Talk

21 Mar 2025, 19:29 UTC

Market Talk

Oil Futures Post Moderate Weekly Gains -- Market Talk

21 Mar 2025, 19:09 UTC

Market Talk

U.S. Natural Gas Futures Grapple With $4 Level -- Market Talk

21 Mar 2025, 19:02 UTC

Market Talk

Gold Eases to End Record-Setting Week -- Market Talk

21 Mar 2025, 18:52 UTC

Market Talk

Telus Downgraded on Leverage, Cash Flow, Dividend Concerns -- Market Talk

21 Mar 2025, 18:49 UTC

Top News

Trump to Announce Multibillion-Dollar Jet Fighter -- Third Update

21 Mar 2025, 18:39 UTC

Market Talk
Earnings

Nike's Aggressive Discounting Of Classics Could Damage Brand -- Market Talk

21 Mar 2025, 18:07 UTC

Top News

Major Indexes Swing Around the Flatline -- WSJ

21 Mar 2025, 18:07 UTC

Market Talk
Earnings

Nike's Focus On Hot New Products May Not Offset Decline In Classic Styles -- Market Talk

21 Mar 2025, 17:41 UTC

Market Talk
Earnings

Nike's Turnaround Messaging May Add Some Confusion -- Market Talk

21 Mar 2025, 17:41 UTC

Top News

Trump to Announce Multibillion-Dollar Jet Fighter -- Second Update

21 Mar 2025, 17:41 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

21 Mar 2025, 17:17 UTC

Market Talk

U.S. Oil Rig Count Slips By One to 486 -- Market Talk

21 Mar 2025, 17:06 UTC

Market Talk

Bitcoin Treads Water After Trump Address -- Market Talk

21 Mar 2025, 16:54 UTC

Market Talk
Earnings

FedEx Assumed an Industrial Ramp Up That Didn't Come -- Market Talk

21 Mar 2025, 16:40 UTC

Market Talk

Mexican Inflation Likely Slowed in Early March -- Market Talk

21 Mar 2025, 16:25 UTC

Top News

Dow, S&P 500 Fall -- WSJ

21 Mar 2025, 16:17 UTC

Top News

NY Fed's Williams Says 'Uncertainty Is High,' Sees Slower GDP Growth -- Barrons.com

Peer Comparison

Price change

Alkermes PLC Forecast

Price Target

By TipRanks

13.86% upside

12 Months Forecast

Average 38.62 USD  13.86%

High 46 USD

Low 30 USD

Based on 13 Wall Street analysts offering 12 month price targets forAlkermes PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

13 ratings

9

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

34.31 / 35.35Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

174 / 387 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.